John David Hassell

age ~67

from Washington, DC

Get Report

Also known as:

John D Hassell
John David Hassell Revocab
John D Hasll

Phone and address:: 1621 19Th St NW, Washington, DC 20009

Connected to:

John Hassell Phones & Addresses

1621 19Th St NW, Washington, DC 20009
Rehoboth Beach, DE
31 Paradise Ave, San Francisco, CA 94131
Palo Alto, CA
Seattle, WA
Santa Clara, CA
Tacoma, WA

Name / Title

Company / Classification

Phones & Addresses

John Hassell
Director

United Nations High Commission for Refugees
Public Relations

1775 K St NW, Washington, DC 20006
2022965191, 2023319363

John Hassell
Manager

Hewlett-Packard Company
Whol Computers to The Government

1100 New York Ave NW, Washington, DC 20005
1331 Pennsylvania Ave NW, Washington, DC 20004
2028847000

Medicine Doctors

John F. Hassell

view source

Specialties:

Family Medicine

Work:

Laurel Family Clinic
1440 Jefferson St, Laurel, MS 39440
6014280577 (phone), 6016497962 (fax)

Education:

Medical School
University of Mississippi School of Medicine
Graduated: 1973

Procedures:

Allergen Immunotherapy
Arthrocentesis
Continuous EKG
Destruction of Benign/Premalignant Skin Lesions
Electrocardiogram (EKG or ECG)
Pulmonary Function Tests
Sigmoidoscopy
Skin Tags Removal
Vaccine Administration
Wound Care

Conditions:

Allergic Rhinitis
Anemia
Atrial Fibrillation and Atrial Flutter
Bronchial Asthma
Disorders of Lipoid Metabolism

Languages:

English

Description:

Dr. Hassell graduated from the University of Mississippi School of Medicine in 1973. He works in Laurel, MS and specializes in Family Medicine. Dr. Hassell is affiliated with South Central Regional Medical Center.

License Records

John B Hassell

Phone:

7273263279

License #:

5211469 - Active

Category:

Health Care

Issued Date:

Aug 13, 2013

Effective Date:

Aug 13, 2013

Expiration Date:

Jul 31, 2017

Type:

Licensed Practical Nurse

Wikipedia

J Hassell

view source

Jon Hassell (born March 22, 1937) is an American trumpet player and composer. He is known for his influence in the world music scene and his unusual ...

Us Patents

Perlecan Transgenic Animals And Methods Of Identifying Compounds For The Treatment Of Amyloidoses
view source
US Patent:

6563016, May 13, 2003
Filed:

Mar 27, 2000
Appl. No.:

09/536231
Inventors:

Alan D. Snow - Lynnwood WA
Ken-Ichiro Fukuchi - Birmingham AL
John Hassell - Tampa FL
Assignee:

University of Washington - Seattle WA
International Classification:

A01K 6700
US Classification:

800 12, 800 8, 800 9, 800 3, 800 14, 800 18, 800 21, 800 22, 800 25, 4353201, 435325, 435455
Abstract:

The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and a amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition.

Perlecan Transgenic Animals And Methods Of Identifying Compounds For The Treatment Of Amyloidoses
view source
US Patent:

7309812, Dec 18, 2007
Filed:

Jul 5, 2006
Appl. No.:

11/481568
Inventors:

Alan D. Snow - Lynnwood WA, US
Ken-Ichiro Fukuchi - Peoria IL, US
John Hassell - Tampa FL, US
International Classification:

C12N 15/00
A01K 67/027
A01K 67/033
G01N 33/00
US Classification:

800 22, 800 3, 800 9, 800 14, 800 18, 800 21
Abstract:

The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

Perlecan Transgenic Animals And Methods Of Identifying Compounds For The Treatment Of Amyloidoses
view source
US Patent:

20030233669, Dec 18, 2003
Filed:

Mar 5, 2003
Appl. No.:

10/384172
Inventors:

Alan Snow - Lynnwood WA, US
Ken-Ichiro Fukuchi - Birmingham AL, US
John Hassell - Tampa FL, US
International Classification:

A01K067/027
US Classification:

800/018000, 800/021000
Abstract:

The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.